A very small fraction of our genetic material - about 2% - performs the crucial task scientists once thought was the sole purpose of the genome: to serve as a blueprint for the production of proteins, the molecules that make cells work and sustain life. This 2% of human DNA is converted into intermediary molecules
Full Post: Scientists uncover new RNA processing mechanism and a new class of small RNAs
Scientists in the United States have discovered that ultrasound waves help dissolve blood clots in deep vein thrombosis (DVT) faster than clot-busting drugs.
According to researchers at Emory University, as such clots are one of the main causes of both heart attacks and stroke, the quicker they are eliminated the better.
Dr. Karthikeshwar Kasirajan, an assistant professor of surgery at Emory University’s School of Medicine says using ultrasound, along with traditional drugs to break up or dissolve blood clots, will help restore blood flow, prevent valve damage and also prevent the possibility of pulmonary embolism.
A DVT is a blood clot that forms in a vein deep in the body, most commonly in the lower leg or thigh - a loose clot, called an embolus, can break off and travel through the bloodstream to the lungs and block the blood flow, causing the life-threatening condition pulmonary embolism - experts say every year, between 350,000 and 600,000 Americans develop one of these clots and at least 100,000 die as a result.
For the study the researchers treated 37 patients with the clot-dissolving drug called tPA (tissue plasminogen activator), while using ultrasound to loosen the proteins in their blood clots and send the drug into the clots faster.
It was discovered that of the 37, 16 had DVT and 21 had acute in-situ arterial thrombosis - all the patients with arterial thrombosis had their clots completely dissolved, and all but six of the DVT patients had theirs completely dissolved.
Four DVT patients had their clots partially dissolved and two saw no change and only one of the 37 had a complication (neck hematoma) - most of the 37 (83%) were subsequently treated with angioplasty and stent placement.
Being immobile for long periods of time, recent surgery, a fall or broken bone, pregnancy, a car crash, birth control pills or menopause hormones are all risk factors for DVT. The risk rises with age, especially over 65, and is more so amongst people who smoke or are obese.
The study was presented at the 4th annual VEITHsymposium in New York City where world-renowned vascular specialists introduce the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques.
--------------------------------------------------------------------------------------------
Related Posts:
Blood transfusions used to treat anemia in patients with cancer are associated with an increased risk of life-threatening blood clots, at a similar rate as other treatments for cancer-induced anemia, according to scientists at the University of Rochester Medical Center. These findings, published in Tuesday’s Archives of Internal Medicine, pose a quandary for doctors who
Full Post: Blood transfusions increase clot risk in hospitalized cancer patients
According to new research by French scientists flu shots may reduce the risk of venous thrombotic embolism. Venous thrombotic embolism (VTE) occurs when blood clots form in veins and is dangerous because the blood clot can break loose and travel through the circulatory system to the right side of the heart - from there to
Full Post: Flu shots cut the risk of blood clots forming in veins
The largest study ever to examine the preventive use of blood-thinning medication to help prevent deadly blood clots in patients with cancer undergoing chemotherapy presented December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Additional research being featured at the press conference includes studies that examine
Full Post: New approaches to prevent blood clots
Deep venous thrombosis (DVT), the formation of blood clots in the lower limbs, is the third-most common vascular disease in North America after heart attack and stroke, and is a frequent complication in hospitalized patients. DVT is a potentially serious condition that can lead to rapid death from pulmonary embolism if untreated, and has become
Full Post: Thrombosis patients face greater risks than previously believed
Aires Pharmaceuticals Inc. today announced the signing of an exclusive license agreement with the U.S. National Institutes of Health for the patented use of a nitric oxide prodrug to treat cardiopulmonary conditions. The technology, identified at the NIH’s National Heart, Blood and Lung Institute, shows that nitrite, which is converted by the body into
Full Post: Aires Pharmaceuticals signs license agreement with NIH --------------------------------------------------------------------------------------------
